- Home
- EXEL vs HST Comparison
EXEL vs HST Comparison
Compare EXEL & HST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | HST |
|---|---|---|
| Founded | 1994 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 11.9B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | HST |
|---|---|---|
| Price | $44.37 | $17.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 13 |
| Target Price | ★ $44.73 | $18.65 |
| AVG Volume (30 Days) | 2.5M | ★ 7.6M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 5.21% |
| EPS Growth | ★ 53.55 | 3.27 |
| EPS | ★ 2.38 | 1.06 |
| Revenue | $2,288,218,000.00 | ★ $5,950,000,000.00 |
| Revenue This Year | $9.14 | $6.31 |
| Revenue Next Year | $12.51 | $1.80 |
| P/E Ratio | $18.67 | ★ $16.31 |
| Revenue Growth | ★ 9.93 | 6.44 |
| 52 Week Low | $31.90 | $12.22 |
| 52 Week High | $49.62 | $19.37 |
Technical Indicators
Market Signals| Indicator | EXEL | HST |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 50.20 |
| Support Level | $43.00 | $17.09 |
| Resistance Level | $44.79 | $17.69 |
| Average True Range (ATR) | 1.03 | 0.37 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 83.48 | 43.53 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.